

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR ACCESS OF ABANDONED APPLICATION UNDER 37 CFR 1.14(a)

RECEIVED

DEC 01 1989

File Information Unit

In re Application of

Application Number

Filed

07-310252 7-13-89

Group Art Unit

Examiner

SK

Paper No. *[Signature]*
*#37*Assistant Commissioner for Patents
Washington, DC 20231

I hereby request access under 37 CFR 1.14(a)(3)(iv) to the application file record of the above-identified ABANDONED application, which is: (CHECK ONE)

- (A) referred to in United States Patent Number 5693762, column _____.
- (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11, i.e., Application No. _____, filed _____, on page _____ of paper number _____.
- (C) an application that claims the benefit of the filing date of an application that is open to public inspection, i.e., Application No. _____, filed _____, or
- (D) an application in which the applicant has filed an authorization to lay open the complete application to the public.

Please direct any correspondence concerning this request to the following address:

[Signature]

Signature

ADRIAN

Typed or printed name

12-1-00

Date

FOR PTO USE ONLY

Approved by: *[Signature]*

Initials	File Information Unit
UNIT	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

US0056937A

United States Patent [19]
Queen et al.

[11] Patent Number: **5,693,762**
[45] Date of Patent: **Dec. 2, 1997**

[54] HUMANIZED IMMUNOGLOBULINS

[75] Inventors: Cary L. Queen, Los Altos; Min Sung Co, Cupertino; William P. Schneider, Mountain View; Nicholas F. Landolfi, Milpitas; Kathleen L. Cooilagh, San Francisco; Harold E. Selick, Belmont, all of Calif.

[73] Assignee: Protein Design Labs, Inc., Mountain View, Calif.

[21] Appl. No. **487,200**

[22] Filed: **Jun. 7, 1995**

Related U.S. Application Data

[63] Continuation of Ser. No. 634,278, Dec. 19, 1990, Pat. No. 5,330,101, which is a continuation-in-part of Ser. No. 590,274, Sep. 28, 1990, abandoned, and Ser. No. 310,252, Feb. 13, 1989, abandoned, which is a continuation-in-part of Ser. No. 290,975, Dec. 28, 1988, abandoned.

[51] Int. Cl. **A61K 39/395**

[52] U.S. Cl. **530/387.3; 530/388.22;**
424/133.1; 424/143.1

[58] Field of Search **530/387.3, 388.22;**
424/133.1, 143.1

[56] References Cited

U.S. PATENT DOCUMENTS

4,378,335	3/1986	Urdal et al.	530/351
4,816,397	3/1989	Boss et al.	433/68
4,816,363	3/1989	Hosjo et al.	433/69.1
4,816,567	3/1989	Cabilly et al.	530/387
4,845,198	7/1989	Urdal et al.	530/387
4,867,973	9/1989	Goers et al.	424/83.91
5,198,399	3/1993	Taniguchi et al.	435/252.3
5,225,539	7/1993	Winter	530/387.3
5,476,786	12/1995	Huston et al.	435/252.33

FOREIGN PATENT DOCUMENTS

0 120 694	10/1984	European Pat. Off.	.
0171496	2/1986	European Pat. Off.	.
0173494	3/1986	European Pat. Off.	.
0184187	6/1986	European Pat. Off.	.
0236634	7/1987	European Pat. Off.	.
0 239 400	9/1987	European Pat. Off.	.
0239400	9/1987	European Pat. Off.	.
0266663	6/1988	European Pat. Off.	.
0 323 806	7/1989	European Pat. Off.	.
0 328 404	8/1989	European Pat. Off.	.
0 363 209	4/1990	European Pat. Off.	.
0 363 997	5/1990	European Pat. Off.	.
0 125 023	6/1991	European Pat. Off.	.
0460167	12/1991	European Pat. Off.	.
2188941	10/1987	United Kingdom.	.
8928874	12/1989	United Kingdom.	.
WO 8605513	9/1986	WIPO.	.
WO 8702671	5/1987	WIPO.	.
WO 8809344	12/1988	WIPO.	.
WO 8901783	3/1989	WIPO.	.
9109967	7/1991	WIPO.	.

OTHER PUBLICATIONS

Groves et al. *Hybridoma* vol. 6 (1) 1987 71.
Chothia, C. and Lesk, A.M., "Canonical Structures for the Hypervariable Regions of Immunoglobulins," *J. Mol. Biol.*, 196:901-917 (1987).

Jones et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse," *Nature*, 321:522-525 (1986).

Jungjans et al., *Cancer Res.*, 50:1495-1502 (1990).
Kupiec-Weglinski et al., *Proc. Natl. Acad. Sci.*, 83:2624 (1986).
Maeda et al., "Construction of reshaped human antibodies with HIV-1 neutralizing activity," *Hum. Antibod. Hybrid.*, 2:124-134 (1991).

Morrison et al., "Chimeric human antibody molecules: Mouse antigen binding-domains with human constant region domains," *Proc. Natl. Acad. Sci.*, 81:6851-6859 (1984).

Morrison, S.L., "Transfected Cells Provide Novel Chimeric Antibodies," *Science*, 229:1202-1207 (1985).

Neuberger et al., "A hapten-specific chimeric IgE antibody with human physiological effector function," *Nature*, 314:268-270 (1985).

Riechmann et al., "Reshaping human antibodies for therapy," *Nature*, 332:323-327 (1988).

Sahagan et al., "A Genetically Engineered Murine/Human Chimeric Antibody Retains Specificity for Human Tumor-Associated Antigen," *J. Immunol.*, 137:1066-1074 (1986).

Verhoeyen et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," *Science*, 239:1534-1536 (1988).

Amit et al., *Science*, 233, 747-753 (1986).

Cheetam, *Protein Engineering*, 2(3), 170-172 (1988).

(List continued on next page.)

Primary Examiner: —Lila Pease

Assistant Examiner: —Julie B. Reeves

Attorney, Agent, or Firm: Townsend & Townsend & Crew

[57] ABSTRACT

Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about about 3 Å as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria. When combined into an intact antibody, the humanized immunoglobulins of the present invention will be substantially non-immunogenic in humans and retain substantially the same affinity as the donor immunoglobulin to the antigen, such as a protein or other compound containing an epitope.